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benefit from anthracyclines in the BR9601
adjuvant breast cancer chemotherapy trial?
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Abstract
Introduction: Predictive cancer biomarkers to guide the right treatment to the right patient at the right time are
strongly needed. The purpose of the present study was to validate prior results that tissue inhibitor of
metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A copy number can be used to
predict benefit from epirubicin (E) containing chemotherapy compared with cyclophosphamide, methotrexate and
fluorouracil (CMF) treatment.
Methods: For the purpose of this study, formalin fixed paraffin embedded tumor tissue from women recruited
into the BR9601 clinical trial, which randomized patients to E-CMF versus CMF, were analyzed for TIMP-1
immunoreactivity. Using previously collected data for HER2 amplification and TOP2A gene aberrations, we defined
patients as “anthracycline non-responsive”, that is, 2T (TIMP-1 immunoreactive and TOP2A normal) and HT (TIMP-1
immunoreactive and HER2 negative) and anthracycline responsive (all other cases).
Results: In total, 288 tumors were available for TIMP-1 analysis with (183/274) 66.8%, and (181/274) 66.0% being
classed as 2T and HT responsive, respectively. TIMP-1 was neither associated with patient prognosis (relapse free
survival or overall survival) nor with a differential effect of E-CMF and CMF. Also, TIMP-1 did not add to the
predictive value of HER2, TOP2A gene aberrations, or to Ki67 immunoreactivity.
Conclusion: This study could not confirm the predictive value of TIMP-1 immunoreactivity in patients randomized
to receive E-CMF versus CMF as adjuvant treatment for primary breast cancer.
Introduction
A number of clinical studies have clearly indicated the
superiority of anthracycline-containing chemotherapy
over the combination of cyclophosphamide, methotrex-
ate and 5-flourouracil (CMF) in adjuvant treatment of
breast cancer [1-3]. However, a significant number of
anthracycline treated patients will experience disease
recurrence, suggesting that their breast cancers con-
tained tumor cells refractory to adjuvant anthracyclines.
Moreover, patients receiving an anthracycline may
experience significant toxicity during treatment [4].
With a validated predictive biomarker for anthracycline
sensitivity/resistance, it would be possible to direct the
toxic adjuvant anthracycline treatment to those patients
with the highest likelihood of a treatment benefit while
those patients with anthracycline resistant tumors could
receive an alternative treatment, for example, a taxane.
A number of studies have suggested that breast cancer
patients with HER2 positive tumors, those amplified and/
or overexpressing HER2, are those obtaining the greatest
benefit from the addition of an anthracycline [5]. Similar
data have been presented for the Topoisomerase IIa
(TIIa) gene copy number (TOP2A) or enzyme, the latter
being a target of the anthracyclines [6]. More recently,
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we have shown that tumor levels of other members of the
HER family may be associated with benefit from adjuvant
chemotherapy [7]. However, these effects are not sub-
stantiated in a recent meta-analysis of multiple trials with
data available for HER2 and TOP2A [8]. Emerging data
may suggest that novel markers associated with centro-
meric enumeration probe for chromosome 17 (CEP17)
duplication may identify, in part, those patients with
anthracycline responsive cancer [9]. However, increas-
ingly, there is recognition of the complex nature of
tumor resistance to chemotherapy and the need for mul-
tiple markers to stratify patients according to their likeli-
hood of response to chemotherapy.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) pro-
tein as determined by immunhistochemistry is another
potential molecular marker for anthracycline benefit
[10]. Preclinical data linked TIMP-1 to protection against
chemotherapy-induced inhibition of apoptosis [11,12],
and when applying TIMP-1 immunohistochemistry
(IHC) to tissue microarrays (TMAs) from the Danish
Breast Cancer Cooperative Group (DBCG) 89D pro-
spective randomized adjuvant trial (cyclophosphamide,
epirubicin, 5-fluorouracil (CEF) vs CMF), [10], it was
demonstrated that women with breast tumors displaying
cancer cell TIMP-1 immunoreactivity had similar benefit
from adjuvant chemotherapy regardless of the addition of
an anthracycline, while women lacking TIMP-1 immu-
noreactivity in the cancer cells had a significant improved
benefit (increased disease free survival (DFS) and overall
survival (OS)) when receiving combination therapy with
an anthracycline as compared with women who received
treatment with CMF [10]. A subsequent study, including
the same DBCG 89D patient cohorts, showed that
TIMP-1 immunhistochemistry could be combined with
the HER2 or TOP2A gene copy number forming a bio-
marker panel which could predict anthracycline benefit
in almost double the number of patients as each of these
markers could do separately [13]. In a more recent study
[14], including patient samples (TMAs) from the Cana-
dian MA5 study in which patients were randomized to
receive either CEF or CMF [14], we reported on a sub-
stantial reduction in mortality by CEF compared to CMF
in patients with a HER2/TIMP-1 or TOP2A/TIMP-1
responsive profile; however, we could not show a simi-
larly significant reduction in recurrence-free survival
events, where a benefit of CEF over CMF was found irre-
spective of TIMP-1 status.
To further test the hypothesis that TIMP-1 in combi-
nation with either HER2 or TOP2A copy number can be
used to predict benefit from adjuvant chemotherapy,
including an anthracycline, we assessed TIMP-1 immu-
noreactivity in TMAs obtained from the BR9601 study
in which patients were randomized to receive either
epirubicin followed by CMF (E-CMF) or CMF alone [2].
On all samples, data on tumor genetic alterations of
HER2 and TOP2A and protein expression of HER2 and
Ki67 were available [7].
Materials and methods
Patients
The BR9601 study recruited 374 pre- and post-menopausal
women with completely excised, histologically confirmed
early breast cancer that had a clear indication for adjuvant
chemotherapy according to current UK practice, which
relies on the Nottingham Prognostic Index for risk stratifi-
cation. For further details, please see [2]. The patients were
randomized between the standard arm of eight cycles of
CMF (intravenous (i.v.) cyclophosphamide 750 mg/m2,
methotrexate 50 mg/m2 and 5-fluorouracil 600 mg/m2)
every 21 days, and E-CMF (four cycles of 100 mg/m2 of
epirubicin every 21 days followed by four cycles of the
same CMF regimen). The protocol was approved by cen-
tral and local ethics committees, and each patient provided
written informed consent prior to randomization. The pri-
mary outcomes of the BR9601 study were relapse free
(RFS) and OS (2). Patients were followed for a mean of
5.30 years (range 2.76 to 8.51 years).
For the current analysis, following approval by the
central ethics committee (South East Multi-centre
Research Ethics Committee), tissue blocks were
retrieved from 321 cases (85.8%) among which 288
cases (77.0%) were applicable for the present study. A
total of 30 samples were lost on the TMAs and 3 cases
had incomplete follow-up. Triplicate tissue microarrays
(TMAs) with 0.6 mm2 cores were constructed using
cores taken from the middle of the invasive tumor fol-
lowing review by a pathologist (JST). Duplicate TMAs
were used for the purpose of this study.
Triple color fluorescent in situ hybridization (FISH)
FISH was performed using a triple-color probe for
HER2, Topoisomerase IIa (TOP2A) and chromosome 17
(CEP17) (Abbot Molecular, Maidenhead, Berkshire, UK)
as previously described [15-17]. Amplifications were
defined as gene:chromosome ratios > 1.5 for TOP2A
and > 2.0 for HER2. TOP2A deletions were defined as
gene:chromosome ratios < 0.8 [17].
Immunohistochemistry
The TIMP-1 immunohistochemistry procedure used has
previously been described in details [18]. In brief, TMAs
were deparaffinized in xylene and rehydrated in graded
concentrations of ethanol. For antigen retrieval, the sec-
tions were microwave treated in citrate buffer pH6 and
endogenous peroxidase activity was blocked by hydrogen
peroxide. IHC staining for TIMP-1 was performed
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overnight at 4°C and used the mouse monoclonal anti-
body, clone VT7 [19] raised against recombinant human
TIMP-1 (0.25 μg/ml).
TIMP-1 staining was scored by two experienced
observers (AB and EB) blinded to patient identity and
outcome. If any TIMP-1 positive cells were evident in
the section it was scored as positive, thus following the
same procedure as in our previous studies [10,13].
The IHC procedure for Ki67 (clone MIB-1, Dako,
Glostrup, Denmark) has been described previously [20].
Staining was scored by a single experienced scorer (AM)
blinded to patient identity and outcome and counting the
percentage of Ki67 positive cells. For Ki67 13% positivity
was used as a cut point for dividing samples into Ki67 low
and high, respectively [20], consistent with our previous
studies.
Statistics
The IBM SPSS (v14) statistical software (IBM corporation,
Portsmouth, Hampshire, UK) was used for statistical ana-
lysis. Kaplan-Meier estimates of survival were used for
analysis of RFS and OS. The Cox’s proportional hazard
model was used to obtain hazard ratios for relapse or
death. When comparing outcomes between the treatment
arms within the two groups of patients identified by bio-
marker expression, formal P-values were not calculated as
in most cases, one group was much smaller than the
other. The Cox model was instead used to identify statisti-
cally significant interactions between biomarkers (expres-
sion or gene alterations) and outcome on the different
treatments (treatment by marker effect), in models that
also included biomarker status (marker effect) and treat-
ment, as covariates.
RFS was calculated from the date of randomization to
the date of relapse or the date last seen. OS was calculated
from the date of randomization to the date of breast can-
cer specific death or the date last seen.
Results
There were no significant differences in patient baseline
characteristics between the overall BR9601 trial population
(n = 374) and the population (n = 288) included in this
biomarker study (Table 1). Of 288 patients included in the
current study, 96 (33.3%) relapsed and 78 (27.1%) died
during the follow-up period. A survival analysis of these
288 patients confirmed the advantage of E-CMF over
CMF observed in the main trial [2] with HR: 0.57; 95% CI
0.37 to 0.86; P = 0.006 and HR: 0.64; 95% CI 0.41 to 1.01;
P = 0.05 for RFS and OS, respectively. All subsequent ana-
lyses are restricted to these 288 cases, or sub-sets thereof.
TIMP1 immunoreactivity
Successful TIMP-1 staining was achieved for 291/321
cases. Three cases were lost to follow-up and excluded
from subsequent analysis. Some TIMP-1 positive tumors
displayed a homogenous staining, while others presented
with a heterogenous staining pattern (Figure 1). Of the
288 cases available for analysis: 42% of the tumors had
one or two TIMP-1 positive cores while 58% presented
with two TIMP-1 negative cores.
HER2, TOP2A and Ki67
Results for HER2 and TOP2A gene copy analyses and
Ki67 protein analysis have been previously presented
and are summarized in Table 2.
Associations between TIMP-1 and Ki67 immunoreactivity
and HER2 and TOP2A gene copy numbers and RFS and OS
The prognostic significance of each of the biological mar-
kers included in this study was first tested on the entire
included patient cohort (n = 288), irrespective of their allo-
cated adjuvant chemotherapy. Exploratory analysis of
these markers (minus TIMP-1) showed the results to be
similar in this cohort and the 321 patients included in the
original biomarker study [7]. TIMP-1 immunoreactivity
was not significantly associated with RFS (HR = 0.83; 95%
CI: 0.55 to 1.24; P = 0.36) or OS (HR = 0.69; 95% CI: 0.43
to 1.09; P = 0.11). However, TIMP-1 positivity was signifi-
cantly associated with an increased number of positive
lymph nodes (P = 0.01), ERa positive disease (P = 0.004),
and decreased proliferation (measured by Ki67; P = 0.004;
Table 3).
Tumors were classified as 2T responsive (TOP2A
abnormal and/or TIMP-1 negative) and 2T non-respon-
sive (TOP2A normal and TIMP-1 immunoreactive) [13].
Using this definition, 183/274 (66.8%) of tumors were
classed as 2T responsive and 91/274 (33.2%) as 2T non-
responsive. There was no significant difference in RFS
(HR = 0.91; 95% CI: 0.585 to 1.417; P = 0.68) and OS
(HR = 0.773; 95% CI: 0.470 to 1.271; P = 0.30) between
patients with the 2T responsive profile when compared
to those with the non-responsive profile. A 2T responsive
Table 1 Patient/tumor characteristics from the BR9601
trial and samples retrieved for the current study
BR9601 TIMP-1 Analysis
Number 374 288
Age 50.9 (44.7 to 56.6) 50.5 (45.0 to 57.0)
E-CMF (1) 183 (48.9%) 140 (48.6%)
CMF (2) 191 (51.1%) 148 (51.4%)
Tumor size (median) 23 (17 to 30) 25 (17 to 30)
Positive nodes 2 (1 to 4) 3 (1 to 4)
Grade 3 (2 to 3) 3 (2 to 3)
NPI 5.30 (4.50 to 5.61) 5.21 (4.50 to 5.60)
ER +ve 202 (54.0%) 158 (54.9%)
ER -ve 119 (31.8%) 96 (33.3%)
ER Unk 53 (14.2%) 34 (11.8%)
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profile was associated with ERa negative disease (P =
0.0001), increased pathological grade (P = 0.005), and
increased proliferation (P = 0.001).
On the basis of TIMP-1 immunoreactivity and HER2
gene copy numbers, 181 (66%) of tumors were classified
as HT responsive (HER2 amplified and/or TIMP-1
negative) and 93 (34%) as HT non-responsive (HER2
negative and TIMP-1 immunoreactive). Patients who
had an HT responsive profile had a significantly
decreased RFS (HR = 1.64; 95% CI: 1.035 to 2.6; P =
0.037) and OS (HR: 2.08; 95% CI: 1.21 to 3.56; P =
0.007) when compared to those with a non-responsive




Panel B: Heterogeneous staining. 
 
Figure 1 Illustrative figures of TIMP1 staining. Panel A: Homogenous staining. Panel B: Heterogeneous staining.
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profile. A HT responsive profile was associated with
ERa negative disease (P = 0.0002), increased pathologi-
cal grade (P = 0.003), and increased proliferation (P =
0.0002).
Treatment by marker analysis of the influence of TIMP-1,
TOP2A and HER2 on RFS and OS benefits of E-CMF over CMF
Subsequent analyses focused on possible differential
effects of the expression of these markers on RFS and
OS between patients receiving E-CMF and those treated
with CMF alone. The results for HER2 and TOP2A gene
copy number counts have been published previously [7].
Hazard ratios for TIMP-1 immunoreactivity and asso-
ciated profiles between patients receiving E-CMF and
CMF alone are summarized in Table 4. Treatment by
marker (TxM) HRs demonstrates that there is no evidence
that lack of TIMP-1 immunoreactivity alone or in combi-
nation with TOP2A or HER2 gene aberrations is predictive
of anthracycline benefit. In patients with TIMP-1 immu-
noreactivity there is a trend towards an increase in RFS
(HR = 0.48; 95% CI: 0.24 to 0.93; Figure 2A) and OS (HR
= 0.46; 95% CI: 0.21 to 1.00) in patients treated with E-
CMF compared to CMF alone. However, a similar trend
for RFS (HR = 0.64; 95% CI: 0.38 to 1.10; Figure 2B) and
OS (HR = 0.78; 95% CI: 0.45 to 1.38) was apparent in
patients whose tumors were negative for TIMP-1 suggest-
ing the trend is associated with benefit from treatment
irrespective of the immunoreactivity of TIMP-1.
Discussion
This study, which included 288/374 of the patients
enrolled in the original BR9601 adjuvant study [2],
failed to confirm the predictive value of TIMP-1 pro-
tein measurements for anthracycline benefit [10,13]
either as a stand-alone biomarker or in combination
with HER2 or TOP2A gene aberrations. It should be
mentioned, however, that in the original biomarker
study of the BR9601, neither HER2 nor TOP2A gene
aberrations were associated with benefit from anthra-
cyclines [7].
Although only 288 of the original 374 patient samples
were available for this study, survival analyses confirmed
the benefit from the addition of an anthracycline to
CMF versus CMF alone in this subset of patients. More-
over, when analyzing the associations between patient
outcome and HER2 and TOP2A gene copy number and
Ki-67 protein in the 288 patients, similar results were
obtained as reported previously [7]. It thus appears that
Table 2 HER2 and TOP2A gene status and Ki67 protein expression in the BR9601 cohort used for this study
Amplified Deleted Normal
HER2 FISH 274/288 (95.1%) 62 (22.6%) 212 (77.4%)
TOP2A FISH 274/288 (95.1%) 25 (9.1%) 48 (17.5%) 201 (73.4%)
High Low
Ki67 284/288 (98.6%) 120 (42.3%) 164 (57.7%)
Table 3 Associations between TIMP-1, Ki-67, HER2 and TOP2A
TIMP-1 Negative TIMP-1 Positive P-value
Ki67 Low 83 (50.6%) 81 (67.5%) 0.004
High 81 (49.4%) 39 (32.5%)
HER2 Normal* 119 (75.8%) 93 (79.5%) 0.470
Amplified 38 (24.2%) 24 (20.5%)
TOP2A Deleted 32 (20.4%) 16 (13.7%) 0.310
Normal 110 (70.1%) 91 (77.8%)
Amplified 15 (9.6%) 10 (8.5%)
Normal includes samples with HER2 deletions and HER2 normal samples.
Table 4 Unadjusted HR estimates of the treatment by marker effects
RFS OS
HR 95% CI TxM (HR) HR 95% CI TxM (HR)
TIMP-1 Negative (n = 167; 58%) 0.642 0.377 to 1.091 1.311 0.784 0.447 to 1.376 1.667
Positive (n = 121; 42%) 0.478 0.247 to 0.927 (0.562 to 3.056) 0.461 0.213 to 1.002 (0.641 to 4.339)
2T Profile Responsive (n = 183; 66.8%) 0.613 0.365 to 1.029 1.022 0.450 0.188 to 1.080 1.579
Non-responsive (n = 91; 33.2%) 0.582 0.277 to 1.221 (0.415 to 2.520) 0.739 0.428 to 1.277 (0.565 to 4.411)
HT Profile Responsive (n = 181; 66.1%) 0.658 0.400 to 1.082 0.902 0.783 0.464 to 1.320 0.577
Non-responsive (n = 93; 33.9%) 0.531 0.235 to 1.200 (0.347 to 2.346) 0.384 0.141 to 1.046 (0.186 to 1.788)
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these 288 patients are representative for the initial study
population.
The TIMP-1 immunostaining was performed using a
validated anti-TIMP-1 monoclonal antibody and a strict
protocol [18] and the scoring of TIMP-1 positivity/nega-
tivity was performed as previously described [10]. How-
ever, among the 288 patients 42% were found positive for
TIMP-1, which is much less than what has previously
A) TIMP-1 negative tumors 
B) TIMP-1 immunoreactive tumors 
Patients   Events Risk Group 
62 14 E-CMF 
59 24 CMF 
Patients   Events Risk Group 
78 22 E-CMF 
89 36 CMF 
Figure 2 Relapse free survival for E-CMF (solid line) versus CMF (dashed line). Panel A: TIMP-1 negative tumors. Panel B: TIMP-1
immunoreactive tumors.
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been reported: in the DBCG 89D patient cohort 75% of
the cases were TIMP-1 positive [10] and a similar distribu-
tion between TIMP-1 positivity/negativity was seen in the
MA5 study [14]. While TIMP-1 immunoreactivity is often
heterogeneous [10] and smaller TMA might impact on
results, the cores used here were similar to those used in
the MA5 study. Also while in the DBCG 89D study [10],
the cores were taken from the invasive front of the tumors
while in the BR9601 and MA5 study sampling was focused
on tumor rich areas. TIMP-1 immunoreactivity was signif-
icantly associated with lower Ki67 immunoreactivity, sug-
gesting that TIMP-1 positive tumors have a lower rate of
proliferation, which in turn might result in reduced sensi-
tivity to chemotherapy. Conversely, in the present study in
which TIMP-1 positive tumors had a non-significant
increased benefit from the E-CMF combination as com-
pared to CMF alone is not explained by increased prolif-
eration of these tumors as evaluated by the Ki67 staining.
An alternative explanation for the discordant results
between the present study and our previous studies
[10,13,14] is that the interaction depends on the regimens
and/or the patient populations studied. The anthracycline
regimens in the DBCG and the BR9601 studies are not
identical, with a greater total dose and duration of epiru-
bicin treatment in the DBCG study [3] as compared to
BR9601 [2]. Furthermore, the DBCG trial recruited only
pre-menopausal node-positive women, and patients did
not receive adjuvant endocrine therapy. Conversely, in
BR9601, both pre- and post-menopausal women were
recruited, including 15% node negative tumors, and all
ER positive cases were to receive five years of tamoxifen.
Another noteworthy disparity between the trials was the
higher percentage of ER positive patients recruited into
BR9601 (54.9%) compared to the DBCG trial (33.7%).
While these differences might explain the discordant
results, there is no obvious a priori explanation as to why
they should.
Conclusions
In conclusion, this validation study of TIMP-1 breast can-
cer cell immunoreactivity as a predictive biomarker for
adjuvant anthracycline benefit did not support the use of
this marker to select patients for anthracycline treatment.
Moreover, this study could not confirm any additive pre-
dictive value by combining TIMP-1 immunoreactivity
with results on HER2 and TOP2A FISH analyses.
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